Latest Integration News

FMR Resources has awarded a drilling contract to Big Bear Drilling for a maiden 4,000-metre diamond drilling campaign targeting a large copper porphyry system in Chile’s Llahuin Project. The program aims to unlock the potential of four high-priority targets using advanced directional drilling techniques.

Elanor Commercial Property Fund reported a $5.4 million statutory loss for FY25 despite a slight increase in Funds from Operations, while navigating a strategic capital raise and an unsolicited takeover offer from the Lederer Group.

Intelligent Monitoring Group Limited (IMG) reported a 44% revenue surge to $174.9 million in FY25, driven by four key acquisitions and organic growth, while investing heavily in AI-powered video monitoring technology.

Evergreen Lithium has secured rights to two promising gold projects in Western Australia’s premier goldfields, significantly boosting its exploration footprint with minimal upfront cash outlay. The acquisitions position the company to leverage historical data and regional infrastructure as it advances toward becoming a gold producer.

Decidr AI Industries has locked in a $3.9 million underwriting agreement with Morgans Corporate Limited to back the exercise of listed options expiring this month, providing crucial funding ahead of its DecidrOS Beta release.

Integral Diagnostics (IDX) reported a robust FY25 with 33.7% revenue growth and operating EBITDA margin expansion, driven by the Capitol merger and organic growth. The company exceeded synergy expectations and outlined a confident outlook amid favourable industry tailwinds.

Integral Diagnostics posts robust FY25 results with strong revenue growth and merger synergies exceeding expectations, setting a confident tone for FY26.

Corporate Travel Management Limited has delayed its FY25 financial results due to potential revenue recognition adjustments in Europe, prompting a voluntary ASX trading suspension.

Integral Diagnostics Limited (ASX – IDX) reported a robust FY25 performance, boosted by its transformative merger with Capitol Health Limited. The company posted strong revenue and profit growth, declared a 4.0 cent final dividend, and outlined strategic priorities including AI adoption and teleradiology expansion.

Rhythm Biosciences has completed critical validation of its ColoSTAT colorectal cancer assay and submitted it for ISO15189 accreditation, paving the way for commercialisation. The test demonstrated strong clinical performance, highlighting its potential as a non-invasive diagnostic tool.

Integrated Research reported steady pro-forma revenue in FY25 despite declines in statutory revenue and profits, driven by a softer renewals book and market uncertainty. The company’s product-led growth strategy gained momentum with new product launches and a major contract renewal.

Integrated Research Limited reported an 18% revenue decline and a 51% drop in net profit for FY25, while unveiling a strategic pivot towards AI-driven product innovation and cloud services.